ERK is involved in EGF-mediated protection of tight junctions, but not adherens junctions, in acetaldehyde-treated Caco-2 cell monolayers

Am J Physiol Gastrointest Liver Physiol. 2011 Jul;301(1):G50-9. doi: 10.1152/ajpgi.00494.2010. Epub 2011 Apr 7.

Abstract

The role of mitogen-activated protein kinases (MAPK) in the mechanism of EGF-mediated prevention of acetaldehyde-induced tight junction disruption was evaluated in Caco-2 cell monolayers. Pretreatment of cell monolayers with EGF attenuated acetaldehyde-induced decrease in resistance and increase in inulin permeability and redistribution of occludin, zona occludens-1 (ZO-1), E-cadherin, and β-catenin from the intercellular junctions. EGF rapidly increased the levels of phospho-ERK1/2, phospho-p38 MAPK, and phospho-JNK1. Pretreatment of cell monolayers with U-0126 (inhibitor of ERK activation), but not SB-202190 and SP-600125 (p38 MAPK and JNK inhibitors), significantly attenuated EGF-mediated prevention of acetaldehyde-induced changes in resistance, inulin permeability, and redistribution of occludin and ZO-1. U-0126, but not SB-202190 and SP-600125, also attenuated EGF-mediated prevention of acetaldehyde effect on the midregion F-actin ring. However, EGF-mediated preservation of junctional distribution of E-cadherin and β-catenin was unaffected by all three inhibitors. Expression of wild-type or constitutively active MEK1 attenuated acetaldehyde-induced redistribution of occludin and ZO-1, whereas dominant-negative MEK1 prevented EGF-mediated preservation of occludin and ZO-1 in acetaldehyde-treated cells. MEK1 expression did not alter E-cadherin distribution in acetaldehyde-treated cells in the presence or absence of EGF. Furthermore, EGF attenuated acetaldehyde-induced tyrosine-phosphorylation of occludin, ZO-1, claudin-3, and E-cadherin. U-0126, but not SB-202190 and SP-600125, prevented EGF effect on tyrosine-phosphorylation of occludin and ZO-1, but not claudin-3, E-cadherin, or β-catenin. These results indicate that EGF-mediated protection of tight junctions from acetaldehyde requires the activity of ERK1/2, but not p38 MAPK or JNK1/2, and that EGF-mediated protection of adherens junctions is independent of MAPK activities.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Acetaldehyde / pharmacology*
  • Actins / metabolism
  • Adherens Junctions / drug effects*
  • Anthracenes / pharmacology
  • Butadienes / pharmacology
  • Caco-2 Cells
  • Cadherins / metabolism
  • Claudin-3
  • Enzyme Inhibitors / pharmacology
  • Epidermal Growth Factor / pharmacology*
  • Extracellular Signal-Regulated MAP Kinases / physiology*
  • Humans
  • Imidazoles / pharmacology
  • Inulin / physiology
  • Membrane Proteins / metabolism
  • Nitriles / pharmacology
  • Occludin
  • Permeability / drug effects
  • Phosphoproteins / metabolism
  • Pyridines / pharmacology
  • Tight Junctions / drug effects*
  • Zonula Occludens-1 Protein
  • beta Catenin / metabolism

Substances

  • Actins
  • Anthracenes
  • Butadienes
  • CLDN3 protein, human
  • Cadherins
  • Claudin-3
  • Enzyme Inhibitors
  • Imidazoles
  • Membrane Proteins
  • Nitriles
  • OCLN protein, human
  • Occludin
  • Phosphoproteins
  • Pyridines
  • TJP1 protein, human
  • U 0126
  • Zonula Occludens-1 Protein
  • beta Catenin
  • pyrazolanthrone
  • Epidermal Growth Factor
  • Inulin
  • Extracellular Signal-Regulated MAP Kinases
  • Acetaldehyde
  • 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole